Showing results (61-70 of 113) with videos related to
Sort By:
Pageof 12
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 12, 2010
Germline polymorphisms in genes involved in the IGF1 pathway predict efficacy of cetuximab in wild-type KRAS mCRC patientsThomas Winder, Wu Zhang, Dongyun Yang, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 7, 2004
A Phase I pharmacokinetic and biological correlative study of oblimersen sodium (genasense, g3139), an antisense oligonucleotide to the bcl-2 mRNA, and of docetaxel in patients with hormone-refractory prostate cancerAnthony W Tolcher, John Kuhn, Garry Schwartz, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 2002
ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trialMalcolm Ranson, Lisa A Hammond, David Ferry, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 11, 2009
A phase I study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced solid malignanciesSanjay Goel, Alain C Mita, Monica Mita, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 5, 2002
Troxacitabine, an L-stereoisomeric nucleoside analog, on a five-times-daily schedule: a phase I and pharmacokinetic study in patients with advanced solid malignanciesJohann S de Bono, Joseph Stephenson, Sharyn D Baker, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 10, 2004
Administration of CI-1033, an irreversible pan-erbB tyrosine kinase inhibitor, is feasible on a 7-day on, 7-day off schedule: a phase I pharmacokinetic and food effect studyEmiliano Calvo, Anthony W Tolcher, Lisa A Hammond, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 10, 2005
Phase 1 study of weekly polyethylene glycol-camptothecin in patients with advanced solid tumors and lymphomasJames A Posey, M Wasif Saif, Ronda Carlisle, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 31, 2002
A phase I and pharmacokinetic study of pegylated camptothecin as a 1-hour infusion every 3 weeks in patients with advanced solid malignanciesEric K Rowinsky, Jinee Rizzo, Leonel Ochoa, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2002
A phase I study of pivaloyloxymethyl butyrate, a prodrug of the differentiating agent butyric acid, in patients with advanced solid malignanciesAmita Patnaik, Eric K Rowinsky, Miguel A Villalona, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 20, 2005
Phase I and pharmacokinetic study of sequences of the rebeccamycin analogue NSC 655649 and cisplatin in patients with advanced solid tumorsAlejandro D Ricart, Lisa A Hammond, John G Kuhn, et al.Pageof 12